Certolizumab Pegol
| Evidence Level: L4 | Predicted Indications: 6 |
Table of Contents
- Certolizumab Pegol
- Certolizumab Pegol: From Inflammatory Autoimmune Diseases to Rheumatoid Vasculitis
Certolizumab Pegol: From Inflammatory Autoimmune Diseases to Rheumatoid Vasculitis
One-Sentence Summary
Certolizumab pegol (Cimzia) is a PEGylated anti-TNF-α antibody fragment, used for inflammatory autoimmune diseases such as Crohn’s disease, rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. The TxGNN model predicts it may be effective for rheumatoid vasculitis, but no trial tests this use, and the literature is mostly case reports of anti-TNF-induced vasculitis, which point the opposite way. Only 1 case report of benefit and 0 relevant clinical trials support this prediction.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Rheumatoid vasculitis |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 2 license records (both under BLA125160) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the input. Certolizumab pegol is a PEGylated, Fc-free Fab’ fragment that neutralizes TNF-α. It is used in several inflammatory autoimmune diseases, and its efficacy in rheumatoid arthritis is established.
Rheumatoid vasculitis is a complication of rheumatoid arthritis, and TNF-α drives inflammation in rheumatoid arthritis. On that basis, TNF blockade is mechanistically plausible for rheumatoid vasculitis.
The clinical picture is more complicated. Most retrieved reports describe vasculitis caused by anti-TNF therapy, including certolizumab pegol (paradoxical reactions). Only one case report describes benefit, in leg ulcers due to rheumatoid vasculitis. The high TxGNN score is a model prediction and is not backed by clinical evidence. The safety signals also point in the opposite direction.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Perioperative immunosuppressant management in rheumatology patients having shoulder arthroplasty. Does not assess vasculitis. |
| NCT05696106 | N/A (observational) | Unknown | 750,000 | Risk of developing other immune-mediated inflammatory diseases while on biologics. Addresses risk, not vasculitis treatment. |
| NCT01579006 | N/A (observational) | Completed | 184 | Non-interventional study of tocilizumab in rheumatoid arthritis. Not certolizumab and not vasculitis. |
None of these trials evaluates certolizumab pegol for rheumatoid vasculitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36597972 | 2022 | Cohort | RMD Open | Long-term follow-up of certolizumab pegol in 80 patients with uveitis due to immune-mediated inflammatory diseases. Indirect evidence. |
| 29610119 | 2018 | Cohort | Clin Med Res | Single-center experience of cutaneous adverse events with biologic agents. |
| 36418084 | 2022 | Review | RMD Open | Comparison of infection frequency and type across immune-modulatory drugs, based on product characteristics data. |
| 34786446 | 2021 | Case report | JAAD Case Rep | Certolizumab pegol used to treat leg ulcers due to rheumatoid vasculitis. This is the only report suggesting benefit. |
| 41158918 | 2025 | Case report | Cureus | Medium-vessel vasculitis induced by anti-TNF therapy (certolizumab pegol) in a woman with seronegative RA. |
| 31990069 | 2020 | Case report | J Clin Pharm Ther | Hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for RA. |
| 28405087 | 2017 | Case report | Proc (Bayl Univ Med Cent) | Leukocytoclastic vasculitis drug reaction to certolizumab pegol. |
| 32687015 | 2021 | Case report | Mod Rheumatol Case Rep | Rapidly progressive glomerulonephritis after starting certolizumab pegol. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| BLA125160 | Cimzia | Injection, solution | UCB, Inc. |
The record appears twice under the same BLA number. No approved indication text was provided in the data.
Safety Considerations
- Literature-based signal: Several case reports describe vasculitis (leukocytoclastic, medium-vessel, urticarial) and glomerulonephritis arising during certolizumab pegol therapy. This is directly relevant to use in vasculitis.
- Infection risk: A product-characteristics review (PMID 36418084) compares infection profiles across immune-modulatory drugs. Serious infection remains a concern.
No drug interaction data were found. For package insert warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high (99.78%), but no trial tests certolizumab pegol in rheumatoid vasculitis. The literature consists of one benefit case report and several reports of anti-TNF-induced vasculitis. The evidence level is L4, and the safety signals argue against the prediction.
To proceed, the following is needed:
- FDA package insert warnings and contraindications, which are currently missing and block safety screening.
- Detailed mechanism of action data (DrugBank).
- Systematic case-series or registry data comparing benefit against paradoxical vasculitis with anti-TNF therapy.
- Confirmed original approved indications from regulatory records.
Note on other predictions in this pack: “Inflammatory spondylopathy” and “vertebral disease” (mainly axial spondyloarthritis) reach L1, with Phase 3 trials NCT01087762 and NCT02505542. “Polyarticular juvenile rheumatoid arthritis” reaches L2, with one completed open-label Phase 3 study (NCT01550003). These look like established uses rather than novel repurposing, so their label status should be verified. “Hypermobility of coccyx” and “Kummell disease” have no evidence (L5) and no plausible TNF-mediated mechanism.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.